| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.47.8.2404-2412.2003 |
| P8608 | Fatcat ID | release_xzrds5cu6bbwdowvzh7pfzfkay |
| P932 | PMC publication ID | 166068 |
| P698 | PubMed publication ID | 12878497 |
| P50 | author | Dominique Sanglard | Q40141436 |
| P2093 | author name string | Jacques Bille | |
| Françoise Ischer | |||
| Derek Falconer | |||
| Tania Parkinson | |||
| P2860 | cites work | Characterization of a cytochrome P450 deficient mutant of Candida albicans. | Q54400298 |
| Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients | Q71832854 | ||
| Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans | Q72697440 | ||
| Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation | Q72989562 | ||
| Loss of heterozygosity, by mitotic gene conversion and crossing over, causes strain-specific adenine mutants in constitutive diploid Candida albicans | Q78104273 | ||
| Biochemical characterization and subcellular localization of the sterol C-24(28) reductase, erg4p, from the yeast saccharomyces cerevisiae. | Q27930059 | ||
| Cloning, disruption and sequence of the gene encoding yeast C-5 sterol desaturase. | Q27931197 | ||
| The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol | Q27936224 | ||
| Functional discovery via a compendium of expression profiles | Q27938962 | ||
| Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors | Q28344744 | ||
| Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site | Q30827584 | ||
| Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents | Q33689421 | ||
| Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. | Q33721804 | ||
| Isogenic strain construction and gene mapping in Candida albicans. | Q33961115 | ||
| Depletion of the squalene synthase (ERG9) gene does not impair growth of Candida glabrata in mice | Q33980488 | ||
| Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients | Q33983022 | ||
| In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata | Q33983303 | ||
| Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. | Q34417276 | ||
| Molecular basis of resistance to azole antifungals | Q34508503 | ||
| Antifungal drug resistance to azoles and polyenes | Q34807486 | ||
| Cross-resistance to polyene and azole drugs in Cryptococcus neoformans | Q35116225 | ||
| Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters | Q35120105 | ||
| Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility | Q35120844 | ||
| Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors | Q35127954 | ||
| Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia | Q35131728 | ||
| Epidemiology of nosocomial fungal infections | Q35372424 | ||
| Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray | Q38300837 | ||
| Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants | Q39558473 | ||
| Biochemical and physiological effects of sterol alterations in yeast--a review | Q40550822 | ||
| Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals | Q41273819 | ||
| Repeated use of GAL1 for gene disruption in Candida albicans | Q41809922 | ||
| Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans | Q47940968 | ||
| Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. | Q54179857 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Candida albicans | Q310443 |
| P304 | page(s) | 2404-2412 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents | |
| P478 | volume | 47 |
| Q90224827 | A Crucial Role for Ergosterol in Plasma Membrane Composition, Localisation, and Activity of Cdr1p and H+-ATPase in Candida albicans |
| Q47274009 | A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. |
| Q41774705 | A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata |
| Q57362291 | A sterol 14α-demethylase is required for conidiation, virulence and for mediating sensitivity to sterol demethylation inhibitors by the rice blast fungus Magnaporthe oryzae |
| Q47609964 | ABC transporters coupled with the elevated ergosterol contents contribute to the azole resistance and amphotericin B susceptibility |
| Q38834811 | Amphotericin forms an extramembranous and fungicidal sterol sponge. |
| Q36235037 | An update on antifungal targets and mechanisms of resistance in Candida albicans |
| Q43476035 | Anaerobic growth of Candida albicans does not support biofilm formation under similar conditions used for aerobic biofilm |
| Q38623199 | Analysis of sphingolipids, sterols and phospholipids in human pathogenic Cryptococcus strains |
| Q42709579 | Anti-Candida properties of asaronaldehyde of Acorus gramineus rhizome and three structural isomers |
| Q37682167 | Antifungal Activity of the Ethanol Extract from Flos Rosae Chinensis with Activity against Fluconazole-Resistant Clinical Candida |
| Q46295052 | Antifungal activity of linalool in cases of Candida spp. isolated from individuals with oral candidiasis. |
| Q37554059 | Antifungal drug resistance: do molecular methods provide a way forward? |
| Q39751373 | Antifungal resistance and new strategies to control fungal infections |
| Q38684281 | Antifungals: Mechanism of Action and Drug Resistance |
| Q34352270 | Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. |
| Q44594097 | Assessment of dentifrices against Candida biofilm. |
| Q34247781 | Azole resistance by loss of function of the sterol Δ⁵,⁶-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence |
| Q48124370 | Azole resistance in Candida albicans from animals: Highlights on efflux pump activity and gene overexpression |
| Q44606676 | Beauvericin counteracted multi-drug resistant Candida albicans by blocking ABC transporters. |
| Q90297410 | Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents |
| Q92921364 | Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal |
| Q33693252 | Candida albicans virulence and drug-resistance requires the O-acyltransferase Gup1p |
| Q42477429 | Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes |
| Q37263791 | Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. |
| Q58490177 | Cdr2p contributes to fluconazole resistance in Candida dubliniensis clinical isolates |
| Q50026385 | Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals |
| Q92238742 | Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae |
| Q35125877 | Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs |
| Q34596791 | Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole |
| Q52647957 | ERG3 and ERG11 genes are critical for the pathogenesis of Candida albicans during the oral mucosal infection. |
| Q40565750 | ERG6 gene deletion modifies Kluyveromyces lactis susceptibility to various growth inhibitors. |
| Q33858493 | Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans |
| Q43418253 | Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia |
| Q26750816 | Emerging Threats in Antifungal-Resistant Fungal Pathogens |
| Q33956119 | Endoplasmic reticulum localized PerA is required for cell wall integrity, azole drug resistance, and virulence in Aspergillus fumigatus. |
| Q38711698 | Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. |
| Q90574541 | Erg6 affects membrane composition and virulence of the human fungal pathogen Cryptococcus neoformans |
| Q47185365 | Essential Oils and Antifungal Activity. |
| Q41925698 | First step of glycosylphosphatidylinositol (GPI) biosynthesis cross-talks with ergosterol biosynthesis and Ras signaling in Candida albicans |
| Q28534687 | Fitness trade-offs restrict the evolution of resistance to amphotericin B |
| Q39092120 | Fluconazole resistance in Candida species: a current perspective |
| Q34352293 | Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance |
| Q33202199 | Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. |
| Q27933729 | Genetic architecture of Hsp90-dependent drug resistance |
| Q49112689 | Genomewide screening for genes involved in biofilm formation and miconazole susceptibility in Saccharomyces cerevisiae |
| Q53690847 | Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs. |
| Q36302013 | Host carbon sources modulate cell wall architecture, drug resistance and virulence in a fungal pathogen |
| Q34290134 | Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans |
| Q40148508 | Identification and Mode of Action of a Plant Natural Product Targeting Human Fungal Pathogens. |
| Q42271039 | Identification and functional characterization of Rca1, a transcription factor involved in both antifungal susceptibility and host response in Candida albicans |
| Q37450682 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species |
| Q36672181 | In search of the holy grail of antifungal therapy |
| Q37598624 | In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance |
| Q36314153 | In vitro inhibitory effects of farnesol and interactions between farnesol and antifungals against biofilms of Candida albicans resistant strains |
| Q33935383 | Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans |
| Q33706569 | Interaction of gelatin with polyenes modulates antifungal activity and biocompatibility of electrospun fiber mats |
| Q38977369 | Isolation, characterization and mechanism of action of an antimicrobial peptide from Lecythis pisonis seeds with inhibitory activity against Candida albicans |
| Q34302880 | It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug |
| Q54201991 | Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity. |
| Q33805788 | Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance |
| Q38559208 | Medically important fungi respond to azole drugs: an update. |
| Q36969703 | Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals |
| Q46458243 | Multilocus resistance evolution to azole fungicides in fungal plant pathogen populations. |
| Q54320722 | Mutual co-regulation between GPI-N-acetylglucosaminyltransferase and ergosterol biosynthesis in Candida albicans. |
| Q52668355 | NSG2 (ORF19.273) Encoding Protein Controls Sensitivity of Candida albicans to Azoles through Regulating the Synthesis of C14-Methylated Sterols. |
| Q35756422 | Nontoxic antimicrobials that evade drug resistance |
| Q89976298 | Novel 2,4-Disubstituted-1,3-Thiazole Derivatives: Synthesis, Anti-Candida Activity Evaluation and Interaction with Bovine Serum Albumine |
| Q36284025 | Optimality principles reveal a complex interplay of intermediate toxicity and kinetic efficiency in the regulation of prokaryotic metabolism |
| Q57174950 | Overexpression or Deletion of Ergosterol Biosynthesis Genes Alters Doubling Time, Response to Stress Agents, and Drug Susceptibility in |
| Q38193337 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. |
| Q39040879 | Polyene susceptibility is dependent on nitrogen source in the opportunistic pathogen Candida albicans |
| Q46925155 | Prevention of Candida albicans biofilm by plant oils. |
| Q33750421 | Proteomic analysis of cytosolic proteins associated with petite mutations in Candida glabrata |
| Q36634450 | Recent insights into the mechanisms of antifungal resistance |
| Q42948674 | Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth |
| Q50054211 | Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications |
| Q36077230 | Resistance Surveillance in Candida albicans: A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital. |
| Q89698018 | Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs |
| Q28472787 | Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence |
| Q36992962 | Role of the RAM network in cell polarity and hyphal morphogenesis in Candida albicans. |
| Q41876856 | Small molecules inhibit growth, viability and ergosterol biosynthesis in Candida albicans |
| Q33622748 | Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance. |
| Q36008037 | Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations |
| Q36407342 | Sterol 14α-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana. |
| Q37122826 | Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance |
| Q34543717 | Structural basis for heterogeneous phenotype of ERG11 dependent Azole resistance in C.albicans clinical isolates |
| Q35875686 | Synergistic Interactions of Eugenol-tosylate and Its Congeners with Fluconazole against Candida albicans |
| Q53553360 | Synergistic anti-candidal activity and mode of action of Mentha piperita essential oil and its major components. |
| Q33836567 | Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. |
| Q34297590 | The contribution of Candida albicans vacuolar ATPase subunit V₁B, encoded by VMA2, to stress response, autophagy, and virulence is independent of environmental pH. |
| Q38752384 | The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen |
| Q46175851 | The effect of plagiochin E alone and in combination with fluconazole on the ergosterol biosynthesis of Candida albicans |
| Q92860014 | The negative cofactor 2 complex is a key regulator of drug resistance in Aspergillus fumigatus |
| Q37189877 | The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn |
| Q36101724 | Transcriptional profiling analysis of Penicillium digitatum, the causal agent of citrus green mold, unravels an inhibited ergosterol biosynthesis pathway in response to citral |
| Q60894849 | Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole |
| Q58772447 | Treatment of Invasive Candidiasis: A Narrative Review |
| Q36396182 | Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. |
| Q28818537 | Widespread Genetic Incompatibilities between First-Step Mutations during Parallel Adaptation of Saccharomyces cerevisiae to a Common Environment |
| Q52813151 | Yeast Gup1(2) Proteins Are Homologues of the Hedgehog Morphogens Acyltransferases HHAT(L): Facts and Implications. |
Search more.